简介：

顾云燕教授，博士生导师，哈尔滨医科大学生物信息科学与技术学院，系统生物学教研室副主任，入选哈尔医科大学星联人才计划。

长期从事复杂疾病（肿瘤、器官纤维化）生物信息学研究。在《Oncogene》、《Briefings in Bioinformatics》等期刊发表研究论文60余篇，其中第一/通讯作者30篇。承担国家自然科学基金项目、黑龙江省自然科学基金等9项科研课题。研究成果获得黑龙江省科学技术奖三等奖、黑龙江省医药卫生科学技术二等奖等。中国抗癌协会肿瘤标志专业委员会青年委员，中国抗癌协会肿瘤标志专业委员会肿瘤测序及大数据分析协作组委员，中国抗癌协会肿瘤标志专业委员会肿瘤标志物临床转化研究协作组委员，黑龙江省女医生协会乳腺肿瘤专委会委员。

个人邮箱：

guyunyan@ems.hrbmu.edu.cn

学习和工作经历：

2003.9-2007.7哈尔滨医科大学基础医学本科

2007.9-2011.6哈尔滨医科大学生物物理学（生物信息方向）博士

2011.7-2012.8哈尔滨医科大学计算系统生物学讲师

2012.9-2017.8哈尔滨医科大学计算系统生物学副教授

2017.9-至今哈尔滨医科大学计算系统生物学教授

主持或参加科研项目及人才计划项目情况：

项目类别、批准号、名称、研究起止年月、获资助金额、项目状态（已结题或在研等）、主持或参加。

1.国家自然科学基金面上基金：基于多组学数据解析合成致活效应在非小细胞肺癌对免疫检查点抑制剂耐药中的作用与机制（32270710）、2023/01-2026/12、54万、在研、主持。

2.国家自然科学基金面上基金：基于基因间遗传互作解析癌症靶向药物耐药机制（61673143）、2017/01-2020/12、61万、结题、主持。

3.国家自然科学基金青年基金：基于蛋白质互作网络识别癌相关共扰动模块并解析其功能协同机制（81201822）、2013/01-2015/12、23万、结题、主持。

4.黑龙江省自然科学基金优秀青年项目:基于癌基因组遗传互作识别PARP抑制剂药效标志并解析耐药机制(YQ2021H005)、2021/7-2024/7、10万、在研、主持。

5.黑龙江省普通本科高等学校青年创新人才培养计划：基于癌基因组共改变模式识别癌细胞耐药标志（UNPYSCT-2017061）、2017/11-2020/10、10万、结题、主持；

6.黑龙江省教育厅科学技术研究项目：基于单样本miRNA表达模式识别乳腺癌生存标志物（12541330）、2014/01-2016/12、2.5万、结题、主持。

7.中国博士后科学基金：胶质母细胞瘤相关功能模块共扰动机制研究（2012M510988）、2012/01-2014/12、5万、结题、主持。

8.黑龙江省政府博士后资助基金：基于癌基因组高通量数据识别癌症治疗靶点

（LRB2011289）、2012/01-2014/12、2万、结题、主持。

9.黑龙江省博士后科研启动金：基于癌基因组高通量数据研究癌细胞耐药机制

（LBH-Q16166）、2017/01-2019/12、7万、结题、主持。

奖项：

1. 2020年6月，黑龙江省医药卫生科学技术二等奖，癌症协同扰动模块分析方法研究及其预后标志识别，顾云燕，戚丽霜，赵章翔，赵文媛，常志强

2. 2017年10月,黑龙江省科学技术奖三等奖，非可控性炎症向癌症转化的分子机制研究，郭政，顾云燕，戚丽霜，赵文媛，梁海海。

3. 2017年3月，哈尔滨医科大学青年科技人才奖。

4. 2016年11月,哈尔滨市科学技术进步三等奖，融合组学挖掘非可控性炎症向癌症转化的分子机制，郭政，顾云燕，戚丽霜，赵文媛，梁海海。

5. 2016年10月，哈尔滨医科大学“三育人”工作先进个人。

6.《启智医“声”——新医学智能教育用具领航者》，第七届黑龙江“互联网+”大学生创新创业大赛，银奖，指导教师。

7.《启智医“声”——新医学智能教育用具领航者》，2021年iCAN全国大学生创新创业大赛黑龙江赛区，三等奖，指导教师

8.基于癌基因组识别靶向药物耐药标志和敏感标志，2019届本科优秀毕业论文，指导教师。

发表文章:

1.Sainan Zhang^#,Mengyue Li^#,Yilong Tan,Juxuan Zhang,Yixin Liu,Wenbin Jiang,Xin Li,Haitao Qi,Lefan Tang,Ran Ji,Wenyuan Zhao,Yunyan Gu^*,Lishuang Qi^*. Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Journal of Molecular Medicine. 2022 Dec;100(12):1755-1769.

2.Bo Chen^#, Pengfei Li^#, Mingyue Liu^#, Kaidong Liu, Min Zou, Yiding Geng, Shuping Zhuang, Huanhuan Xu, Linzhu Wang, Tingting Chen, Yawei Li, Zhangxiang Zhao, Lishuang Qi^*,Yunyan Gu^*.A genetic map of the chromatin regulators to drug response in cancer cells. Journal of Translational Medicine. 2022 Sep 30;20(1):438.

3.Tingting Chen^#,Tong Yu^#,Shuping Zhuang,Yiding Geng,Junwen Xue,Jiayi Wang,Liqiang Ai,Bo Chen,Zhangxiang Zhao,Yawei Li,Jinghao Wang,Haihai Liang,Yan Xu^*,Yunyan Gu^*. Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade. British Journal of Cancer. 2022 Sep;127(5):916-926.

4.Kaidong Liu^#, Yiding Geng^#, Linzhu Wang^#, Huanhuan Xu, Min Zou, Yawei Li, Zhangxiang Zhao, Tingting Chen, Fengyan Xu, Liang Sun, Shuliang Wu^*,Yunyan Gu^*. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology. 2022 Aug;16(16):3034-3051.

5.Hailong Zheng^#, Jiajing Xie^#, Kai Song, Jing Yang, Huiting Xiao, Jiashuai Zhang, Keru Li, Rongqiang Yuan, Yuting Zhao,Yunyan Gu^*and Wenyuan Zhao^*. StemSC: a cross-dataset human stemness index for single-cell samples. Stem Cell Research & Therapy. 2022 Mar 21;(2022)13:115.

6.Chengyu Wang^#,Tong Zhu^#,Zhangxiang Zhao^#,Bo Chen,Tingting Chen,Qi Dong,Mingyue Liu,Shuping Zhuang,Fan Yang,Yaoyao Liu,Min Yang,Yunyan Gu^*,Haihai Liang^*. Pan-cancer multi-omics analyses reveal crosstalk between the Hippo and immune signaling pathways in the tumor microenvironment. FEBS Letters. 2022 Feb;596(4):449-464.

7.Shuping Zhuang#, Tingting Chen#, Yawei Li#, Yuquan Wang, Liqiang Ai, Yiding Geng, Min Zou, Kaidong Liu, Huanhuan Xu, Linzhu Wang, Zhangxiang Zhao,Zhiqiang Chang^*,Yunyan Gu^*. Atranscriptional signature detects homologous recombination deficiencyin pancreatic cancerat the individual level. Molecular Therapy-Nucleic Acids. 2021 Oct 20;26:1014-1026.

8.Yawei Li#, Zhangxiang Zhao#, Liqiang Ai, Yuquan Wang, Kaidong Liu, Bo Chen, Tingting Chen, Shuping Zhuang, Huanhuan Xu, Min Zou,Yunyan Gu^*, Xia Li*. Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer. iScience. 2021 Sep 17;24(10):103135.

9.Qi Dong#,Mingyue Liu#,Bo Chen#,Zhangxiang Zhao,Tingting Chen,Chengyu Wang,Shuping Zhuang,Yawei Li,Yuquan Wang,Liqiang Ai,Yaoyao Liu1,Haihai Liang,Lishuang Qi,Yunyan Gu^*. Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. 2021 Aug 10;19:4435-4446. 

10.Zhangxiang Zhao#,YingYing Guo#,Yaoyao Liu#,Lichun Sun,Bo Chen,Chengyu Wang,Tingting Chen,Yuquan Wang,Yawei Li,Qi Dong,Liqiang Ai,Ran Wang,Yunyan Gu^*, Xia Li*. Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer. Oncogene. 2021 Jul;40(27):4604-4614.

11.Tingting Chen#,Yingying Guo#,Jiayi Wang#,Liqiang Ai,Lu Ma,Wenxin He,Zhixin Li,Xiaojiang Yu,Jinrui Li,Xingxing Fan,Yunyan Gu^*,Haihai Liang*. LncRNA CTD-2528L19.6 prevents the progression of IPF by alleviating fibroblast activation.Cell Death & Disease. 2021 Jun 10;12(6):600.

12.Tingting Chen#, Zhangxiang Zhao#, Bo Chen, Yuquan Wang, Fan Yang, Chengyu Wang, Qi Dong, Yaoyao Liu, Haihai Liang, Wenyuan Zhao, Lishuang Qi, Yan Xu*,Yunyan Gu^*. An individualized transcriptional signature to predict the epithelial-mesenchymal transition based on relative expression ordering. Aging (Albany NY). 2020 Jul 8;12(13):13172-13186.

13.Haihai Liang#, Mengxue Yu#, Rui Yang#, Lu Zhang , Lijia Zhang, Di Zhu, Hongwei Luo, Yaozhen Hong, Tong Yu, Jian Sun, Hongli Shan,Yunyan Gu^*. A PTAL-miR-101-FN1 axis promotes EMT and invasion-metastasis in serous ovarian cancer. Molecular Therapy–Oncolytics. 2019 Dec 11;16,53-62.

14.Chengyu Wang^#, Fan Yang^#, Tingting Chen, Qi Dong, Zhangxiang Zhao, Yaoyao Liu, Bo Chen, Haihai Liang, Huike Yang^*, Yunyan Gu^*. RHPCG: a database of the Regulation of the Hippo Pathway in Cancer Genome. Database (Oxford). 2019 Jan 1;2019:baz135.

15.Yue Han^#, Chengyu Wang^#, Qi Dong^#, Tingting Chen, Fan Yang, Yaoyao Liu, Bo Chen, Zhangxiang Zhao, Lishuang Qi, Wenyuan Zhao, Haihai Liang, Zheng Guo^*,Yunyan Gu^*. ­­­Genetic interactions-based biomarkers identification for drug resistance and sensitivity in cancer cells. Molecular Therapy-Nucleic Acids. 2019 Sep 6;17:688-700.

16.Ruiping Wang^#, Yue Han^#, Zhangxiang Zhao, Fan Yang, Ya Han, Tingting Chen, Xianlong Wang, Lishuang Qi, Wenyuan Zhao, Zheng Guo^*,Yunyan Gu^*. Link synthetic lethality to drug sensitivity of cancer cells. Briefings in Bioinformatics. 2019 Jul 19;20(4):1295-1307.

17.Haihai Liang^#, Tong Yu^#, Yue Han^#, Hua Jiang, Chengyu Wang, Tianiyi You, Xiaoguang Zhao, Huitong Shan, Rui Yang, Lida Yang, Hongli Shan,Yunyan Gu^*. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Molecular Cancer. 2018 Aug 11;17(1):119.

18.Yunyan Gu^#, Ruiping Wang^#, Yue Han, Wenbin Zhou, Zhangxiang Zhao, Tingting Chen, Yuanyuan Zhang, Fuduan Peng, Haihai Liang, Lishuang Qi, Wenyuan Zhao, Da Yang^*, Zheng Guo^*.A landscape of synthetic viable interactions in cancer. Briefings in Bioinformatics. 2018 Jul 20;19(4):644-655.

19.Haihai Liang^#, Xiaoguang Zhao^#, Chengyu Wang^#, Jian Sun, Yingzhun Chen, Guoyuan Wang, Lei Fang, Rui Yang, Mengxue Yu,Yunyan Gu^*, Hongli Shan^*. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer. Molecular Cancer. 2018 Jun 21;17(1):96.

20.Wenbin Zhou^#, Zhangxiang Zhao^#, Ruiping Wang, Yue Han, Chengyu Wang, Fan Yang, Ya Han, Haihai Liang, Lishuang Qi, Chenguang Wang, Zheng Guo^*,Yunyan Gu^*. Identification of driver copy number alterations in diverse cancer types and application in drug repositioning. Molecular oncology. 2017 Oct;11(10):1459-1474.(Cover Image)

21.Fuduan Peng^#, Ruiping Wang^#, Yuanyuan Zhang^#, Zhangxiang Zhao, Wenbin Zhou, Zhiqiang Chang, Haihai Liang, Wenyuan Zhao, Lishuang Qi, Zheng Guo^*,Yunyan Gu^*. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Molecular Cancer. 2017 Jun 6;16(1):98.

22.Zhangxiang Zhao^#, Wenbin Zhou^#, Yue Han, Fuduan Peng, Ruiping Wang, Ruihan Yu, Chengyu Wang, Haihai Liang, Zheng Guo^*,Yunyan Gu^*. EMT-Regulome: a database for EMT-related regulatory interactions, motifs and network. Cell Death & Disease. 2017 Jun 15;8(6):e2872.

23.Fuduan Peng, Yuanyuan Zhang, Ruiping Wang, Wenbin Zhou, Zhangxiang Zhao, Haihai Liang, Lishuang Qi, Wenyuan Zhao, Hongwei Wang, Chenguang Wang, Zheng Guo^*,Yunyan Gu^*. Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine. Oncogenesis. 2016 Feb 15;5(2):e194.

24.Yunyan Gu^*#, Pengfei Li^#, Fuduan Peng, Mengmeng Zhang, Yuanyan Zhang, Haihai Liang, Wenyuan Zhao, Lishuang Qi, Hongwei Wang, Chenguang Wang, Zheng Guo^*. Autophagy-related prognostic signature for breast cancer. Molecular Carcinogenesis.2016 Mar;55(3):292-299.

25.Yunyan Gu^*#, Mengmeng Zhang^#, Fuduan Peng, Lei Fang, Yuanyuan Zhang, Haihai Liang, Wenbin Zhou, Lu Ao, Zheng Guo^*. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 2015;6:2397-406.

26.Haihai Liang^#,Yunyan Gu^#, Tianyu Li, Ying Zhang, Longtao Huangfu, Meiyu Hu, Dandan Zhao, Yang Chen, Shanshan Liu, Yuechao Dong, Li Xuelian, Lu Yanjie, Yang Baofeng^*, Shan Hongli^*. Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis. Cell Death & Disease. 2014 May 22;5(5):e1238.

27.Yunyan Gu^*, Hongwei Wang, Yao Qin, Yujing Zhang, Wenyuan Zhao, Lishuang Qi, Yuannv Zhang, Chenguang Wang, Zheng Guo^*. Network analysis of genomic alteration profiles reveals co-altered functional modules and driver genes for glioblastoma. Molecular Biosystems. 2013;9:11.

28.Yunyan Gu^#, Wenyuan Zhao, Jiguang Xia, Yuannv Zhang, Ruihong Wu, Chenguang Wang, Zheng Guo^*. Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. Human Mutation. 2011 Sep;32:8.

29.Yunyan Gu^#, Da Yang^#, Jinfeng Zou, Wencai Ma, Ruihong Wu, Wenyuan Zhao, Yuannv Zhang, Hui Xiao, Xue Gong, Min Zhang, Zhu Jing, Zheng Guo^*. Systematic interpretation of comutated genes in large-scale cancer mutation profiles. Molecular Cancer Therapeutics. 2010 Aug;9(8):2186-95.

30.顾云燕，郭政，赵文媛，杨凡，韩月。乳腺癌个体中差异表达lncRNA的研究。国际遗传学杂志，2017年10月15日第40卷第5期。

^*通讯作者，^#并列第一作者